Quick Answer
Wegovy cash price without insurance is about $199/mo for the first 2 months then $349/mo through NovoCare (list is ~$1,350/mo). Zepbound cash price is $349 to $499/mo flat through LillyDirect. Ozempic runs ~$1,000/mo with no dedicated cash program. Compounded semaglutide starts near $99/mo.
Short answer: Ozempic runs about $1,000/month, Wegovy runs $1,350 at list price but drops to $199 the first two months through NovoCare, and Zepbound is $499/month flat through LillyDirect. Long answer below, with every cash program, every manufacturer hack, and the July 2026 Medicare change that rewrites the whole picture.
🔑 Key Takeaways
- Ozempic without insurance: Roughly $1,000/month at list price. No dedicated manufacturer cash program. Lowest-cost paths are off-brand compounded semaglutide ($99 to $269/month) or prior authorization through a T2D diagnosis
- Wegovy without insurance: $1,350/month list. NovoCare cash program cuts it to $199/month for months 1 to 2, then $349/month from month 3 onward. High-dose 7.2 mg Wegovy runs $399/month. Oral Wegovy tablet starts at $149/month
- Zepbound without insurance: $1,060/month list. LillyDirect single-dose vial is $349/month for the 2.5 mg starting dose and $499/month flat for all doses 5 mg and above. Also now available for retail pickup through Walmart Pharmacy as of October 2025
- July 1, 2026 is the game-changer for Medicare beneficiaries. The Medicare GLP-1 Bridge Program kicks in and covers Wegovy, Zepbound KwikPen, and Foundayo at roughly $50/month copay for eligible enrollees
- Compounded alternatives exist for semaglutide ($99 to $269/month) and tirzepatide ($150 to $399/month). FDA enforcement tightened in 2025, so source quality matters more than ever
- Commercial insurance with prior authorization typically brings all three drugs to $25 to $250/month copay. Ozempic is the easiest to get approved (T2D diagnosis), Wegovy and Zepbound require weight-management PA
- The cheapest legitimate path for most uninsured patients in 2026: compounded semaglutide at $99-$269/month, NovoCare Wegovy at $199/month (first 2 months), or LillyDirect Zepbound at $499/month
This page is the full 2026 cost breakdown for the three most-searched GLP-1 drugs without insurance: real list prices, every manufacturer cash program, the July 2026 Medicare change, compounded alternatives, and exactly how much you will actually pay through each path.
Telehealth Comparison Table
If you'd rather skip the research-vial route, here are the two telehealth providers our readers use most for compounded semaglutide and tirzepatide.
How Much Is Ozempic Without Insurance?
About $1,000 per month at list price.
Ozempic's list price is approximately $1,000 for a month's supply (the exact figure varies slightly based on pharmacy and formulation, but this is the working number without insurance or manufacturer assistance). Unlike Wegovy (which is Novo Nordisk's weight-loss brand) or Zepbound (Eli Lilly's weight-loss brand), Ozempic does not have a dedicated manufacturer cash-pay program.
Ozempic Pricing Options (2026)
- List price: ~$1,000/month (varies by pharmacy)
- Commercial insurance copay with T2D diagnosis: $25 to $200/month with prior authorization
- Medicare Part D: Covered for type 2 diabetes; copay varies by plan
- Medicaid: Covered in most states for type 2 diabetes
- Manufacturer savings card: Novo Nordisk savings card for commercial insurance holders, not cash-pay
- GoodRx / SingleCare discounts: Modest (5 to 15% off list), typically $850 to $950/month range
- Cash-pay cheaper alternative: Compounded semaglutide at $99 to $269/month through licensed compounding pharmacies
Why Ozempic costs more than Wegovy cash-pay even though they contain the same molecule (semaglutide): Wegovy's NovoCare program is an obesity-specific manufacturer subsidy designed to compete in the weight-loss market. Ozempic is indicated for type 2 diabetes where most patients are insured, so there is no equivalent cash program. People paying cash for Ozempic are often doing off-label weight loss without a T2D diagnosis, which insurance typically denies.
For a detailed breakdown of semaglutide pricing across indications, see our dedicated Ozempic cost 2026 guide.
How Much Is Wegovy Without Insurance?
$1,350 at list price, but the real answer is $199 to $349 for most cash-paying patients.
Wegovy's list price is about $1,350 per month, but almost no one pays list. Novo Nordisk's NovoCare cash program for uninsured or underinsured patients is substantially cheaper.
Wegovy Pricing Options (2026)
- List price: ~$1,350/month
- NovoCare cash pay (new patients, pen):
- Months 1 to 2: $199/month (starting doses 0.25 and 0.5 mg)
- Month 3 onward: $349/month (doses 0.25 to 2.4 mg)
- Wegovy HD 7.2 mg (high-dose): $399/month
- Wegovy oral tablet (1.5 mg pill): starts at $149/month with NovoCare
- Commercial insurance copay: $25 to $250/month with prior authorization; as low as $25/month with manufacturer copay savings card (up to $100/month savings, commercial insurance only, government beneficiaries excluded)
- Medicare: Starting July 1, 2026, covered under the Medicare GLP-1 Bridge Program at roughly $50/month copay for eligible beneficiaries
- Medicaid: Varies by state; some states cover for obesity, others restrict to T2D
The NovoCare path is the headline number. For a cash-paying patient, $199 for the first two months and $349 after is dramatically better than the $1,350 list. The pill option at $149/month is even cheaper if oral delivery matches your preference and your doctor prescribes it. Both programs require a valid prescription and enrollment through NovoCare directly.
How Much Is Zepbound Without Insurance?
$1,060 at list price, or $499 flat through LillyDirect for most doses.
Eli Lilly's Zepbound has the cleanest cash-pay structure of the three drugs. LillyDirect sells single-dose vials at flat rates, which means your cost does not climb as you titrate up to higher doses.
Zepbound Pricing Options (2026)
- List price (prefilled pen): ~$1,060/month
- LillyDirect single-dose vial (cash pay):
- 2.5 mg starting dose: $349/month
- 5, 7.5, 10, 12.5, or 15 mg: $499/month flat
- Walmart Pharmacy pickup (launched October 2025): Same LillyDirect pricing ($349/$499) available for in-person pickup through Walmart Pharmacy, in addition to home delivery
- Commercial insurance copay: $25 to $250/month with weight-management prior authorization
- Lilly Zepbound Savings Card: Commercial insurance only, can reduce copay significantly
- Medicare: Zepbound KwikPen covered under the Medicare GLP-1 Bridge starting July 1, 2026, at roughly $50/month copay
- Medicaid: Varies by state
The LillyDirect vial format requires you to draw your own dose with a syringe from a single-use vial, which is a learning curve but not a difficult one. The price advantage is material: $499/month flat at the 15 mg dose versus $1,060 list for the pen. Patients pay the same $499 whether they are on 5 mg, 10 mg, or 15 mg, which makes budgeting predictable.
The October 2025 Walmart Pharmacy expansion added in-person pickup for LillyDirect. Before that, LillyDirect was home-delivery only. Now eligible patients with a valid prescription can pick up Zepbound vials at Walmart at the same direct-to-consumer prices. For tirzepatide-specific pricing breakdowns, see tirzepatide cost without insurance.
Quick Comparison: All Three Drugs Without Insurance
| Drug | List price | Cheapest cash program | With commercial insurance | Medicare (July 2026+) |
|---|---|---|---|---|
| Ozempic (semaglutide, T2D) | ~$1,000/month | No dedicated program. Compounded alternative: $99-$269 | $25-$200 copay with T2D PA | Covered for T2D only |
| Wegovy (semaglutide, weight loss) | ~$1,350/month | NovoCare: $199 (mo 1-2), $349 (mo 3+), $399 (HD 7.2 mg), $149 (pill) | $25-$250 copay with weight-management PA | ~$50 copay via GLP-1 Bridge |
| Zepbound (tirzepatide, weight loss) | ~$1,060/month | LillyDirect vial: $349 (2.5 mg), $499 flat (5-15 mg) | $25-$250 copay with weight-management PA | KwikPen: ~$50 copay via GLP-1 Bridge |
12-Month Total Cost Without Insurance (2026)
Monthly figures hide the real number you care about: what a full year of treatment costs out of pocket. The table below projects 12-month totals for each cash path, assuming you titrate to a maintenance dose within the first two months.
| Path | Months 1 to 2 | Months 3 to 12 | 12-month total |
|---|---|---|---|
| Wegovy cash price via NovoCare | $199/mo ($398) | $349/mo ($3,490) | ~$3,888/year |
| Wegovy oral 1.5 mg tablet (NovoCare) | $149/mo ($298) | $149/mo ($1,490) | ~$1,788/year |
| Zepbound cash price via LillyDirect | $349/mo ($698) | $499/mo ($4,990) | ~$5,688/year |
| Ozempic list price (no cash program) | $1,000/mo ($2,000) | $1,000/mo ($10,000) | ~$12,000/year |
| Compounded semaglutide (licensed pharmacy) | $99 to $269/mo | $99 to $269/mo | ~$1,188 to $3,228/year |
| Compounded tirzepatide (licensed pharmacy) | $150 to $399/mo | $150 to $399/mo | ~$1,800 to $4,788/year |
| Medicare GLP-1 Bridge (Wegovy / Zepbound, from July 1, 2026) | ~$50/mo copay | ~$50/mo copay | ~$600/year |
The headline takeaway on annual cost: the cheapest branded cash path for a full year is the Wegovy oral tablet at roughly $1,788, followed by the Wegovy injectable via NovoCare at about $3,888 and Zepbound via LillyDirect at about $5,688. Paying full list for Ozempic without a cash program runs roughly $12,000 a year, which is why most uninsured patients move to a manufacturer cash program, compounded semaglutide or tirzepatide, or wait for the Medicare GLP-1 Bridge. For the lowest possible annual spend, see our breakdowns of the cheapest GLP-1 in 2026 and the cheapest tirzepatide.
Cash-Pay Manufacturer Programs: NovoCare vs LillyDirect
The two programs work differently.
Wegovy NovoCare
- Tiered pricing: lower price for first 2 months (starting doses), then a step up once you hit maintenance dose
- Requires enrollment through NovoCare portal and a valid Wegovy prescription
- Available for uninsured patients and those whose insurance will not cover Wegovy for weight management
- Does not stack with commercial insurance copay savings card (you pick one or the other)
- Government beneficiaries (Medicare/Medicaid) not eligible, but those patients have the GLP-1 Bridge Program starting July 2026
Zepbound LillyDirect
- Flat pricing: $349 for starting dose, $499 flat for all other doses
- Vial format (not pen) for the direct-to-consumer option. Patients draw dose with syringe
- Available for home delivery or Walmart Pharmacy pickup (since October 2025)
- Must have a valid on-label prescription and meet eligibility requirements for higher doses
- No step-up cost as you titrate; budgeting is predictable across all dosing phases
Which is cheaper depends on what you need. Wegovy NovoCare wins the first 2 months ($199 vs $349). Zepbound LillyDirect wins for anyone on 5 mg or higher (flat $499 vs Wegovy NovoCare's $349 or $399). For maximum weight loss (tirzepatide producing ~20% vs semaglutide's ~15% in head-to-head), Zepbound is the stronger drug, which factors into the cost-per-pound-lost calculation.
Medicare GLP-1 Bridge: The July 2026 Change
Historically Medicare did not cover weight-loss drugs. That changes July 1, 2026.
The Medicare GLP-1 Bridge Program launches July 1, 2026, and covers Wegovy, Zepbound KwikPen, and Foundayo (Eli Lilly's oral GLP-1 tablet) for eligible Medicare Part D beneficiaries. Expected copay is roughly $50/month, with the federal government subsidizing the balance. Eligibility criteria include BMI thresholds similar to commercial insurance weight-management PAs.
This is the single biggest cost change in 2026 for Medicare-enrolled patients. Before July 2026, Medicare patients paid cash ($199 NovoCare or $499 LillyDirect) or had no coverage for weight-loss use. After July 2026, that drops to around $50/month copay.
Medicare Ozempic coverage for type 2 diabetes was always available and remains unchanged. The Bridge program specifically addresses the weight-loss-indicated drugs (Wegovy and Zepbound weight-loss formulations) that previously had no Medicare coverage.
Compounded Semaglutide and Tirzepatide: The Cheapest Path
Not for everyone, but materially cheaper.
Licensed 503A and 503B compounding pharmacies make off-brand versions of semaglutide and tirzepatide. The active molecule is the same; the difference is the delivery format (vial and syringe instead of pre-filled pen) and the regulatory pathway.
- Compounded semaglutide: $99 to $269/month
- Compounded tirzepatide: $150 to $399/month
The 2025 FDA declaration that the semaglutide and tirzepatide shortages were resolved tightened the legal pathway for mass compounding. Personalized prescriptions from physicians are still a valid pathway. Source only from pharmacies with independent HPLC verification, USP 797 sterile compounding certification, and verifiable state board licensure. Avoid anything marketed with lab-only disclaimers or salt-form labels (semaglutide sodium, semaglutide acetate), which are different molecules with documented adverse event reports.
For a complete vendor vetting walkthrough, see our best legit peptide vendors guide.
How to Pay Less Than List Price
Seven concrete strategies that actually work in 2026.
- Enroll in NovoCare (Wegovy) or LillyDirect (Zepbound) the first week your prescription is written. These are the largest immediate savings for uninsured patients.
- Get prior authorization for commercial insurance before filling cash. A well-documented PA (BMI, comorbidity, prior lifestyle intervention) usually succeeds on appeal even if initially denied.
- Ask your prescriber for the oral Wegovy tablet if needle avoidance is a factor and cost matters. At $149/month through NovoCare, it is the cheapest branded GLP-1 in the weight-loss category.
- Request Ozempic if you have a T2D diagnosis rather than Wegovy, even for weight management. Insurance coverage is dramatically easier and copays are usually lower.
- If on Medicare, wait until July 2026 when the GLP-1 Bridge Program launches, unless weight loss is urgent. The copay drops from $500+ to around $50/month for eligible beneficiaries.
- Consider compounded semaglutide or tirzepatide through a reputable licensed compounding pharmacy if you need the molecule at the lowest possible price and accept vial-and-syringe administration.
- Use manufacturer copay savings cards (Novo Nordisk or Lilly) if you have commercial insurance. These stack on top of the PA-approved copay and can bring it to $25/month.
What About Other GLP-1 Drugs?
For reference, the full class cost breakdown:
- Saxenda (liraglutide, daily weight loss injection): ~$1,350 list. Generic liraglutide (Hikma) since December 2024 starts around $250/month cash. Full details in our liraglutide (Saxenda, Victoza) page.
- Mounjaro (tirzepatide, T2D): ~$1,020 list. No dedicated cash program (same situation as Ozempic). Patients commonly switch to Zepbound LillyDirect for the $499 flat pricing.
- Foundayo (orforglipron, oral GLP-1): List price not yet public. Medicare Bridge coverage from July 2026 at ~$50/month.
- Rybelsus (oral semaglutide, T2D): ~$900 list. Similar situation to Ozempic.
- Trulicity, Byetta, Bydureon: T2D-only, typically $800 to $1,000/month list, with commercial insurance and Medicare Part D coverage for T2D.
For the broader comparison landscape, see our GLP-1 weight loss peptides comparison.
NovoCare and LillyDirect: How the Cash-Pay Programs Actually Work
NovoCare and LillyDirect are the two manufacturer cash-pay programs that changed the math for Ozempic, Wegovy, and Zepbound buyers without commercial insurance coverage. They are not identical, and the differences matter when you are choosing which medication to start.
NovoCare (Novo Nordisk): Covers Wegovy and Ozempic. Wegovy is priced at $199 per month for all doses if you order through the NovoCare pharmacy and use the autoinjector pen. The single-dose vial program for Wegovy and Ozempic runs $349 per month for the lower doses (0.25 mg and 0.5 mg semaglutide) and $499 for the higher doses, sold through participating pharmacies. NovoCare does not require uninsured status, but it does require that your insurance not cover the medication (so people with denied prior authorizations qualify too).
LillyDirect (Eli Lilly): Covers Zepbound and Mounjaro. Zepbound Self-Pay vials run $349 per month for 2.5 mg and 5 mg doses, $499 for 7.5 mg through 15 mg. Mounjaro Self-Pay vials use the same tier pricing. LillyDirect ships directly to patients through its partner pharmacy and accepts cash payments only (no insurance billing). The KwikPen autoinjector format is not available through the Self-Pay program, only the single-dose vials, which require manual draw with a syringe.
The practical effect is that the cheapest entry point for any of these drugs in 2026 is Wegovy at $199 through NovoCare. The cheapest tirzepatide path is Zepbound vials at $349 through LillyDirect. If you are price-sensitive and have not committed to either molecule, that $150 monthly delta is the simplest place to start. See our GLP-1 without insurance guide for the full pricing matrix across every program.
Cash-Pay GLP-1 Decision Tree for 2026
The right cash-pay program depends on three things: what your doctor will prescribe, whether you need the autoinjector pen, and whether you have a comorbidity that makes one molecule a better fit. Here is the practical decision tree most prescribers walk patients through.
- Diabetes diagnosis? If yes, Ozempic or Mounjaro is the on-label choice and Part D usually covers them. Skip the cash-pay path unless your plan denied coverage.
- BMI 30 or higher (or 27+ with comorbidity)? You qualify for Wegovy or Zepbound by FDA label. Move to step 3.
- Need the pen autoinjector? If yes, Wegovy through NovoCare ($199/month) is the cheapest pen option. Zepbound KwikPen is only available with insurance or full retail (~$1,060).
- Comfortable drawing from a vial? Zepbound Self-Pay vials at $349 to $499 give you tirzepatide (the more potent molecule) at a moderate premium over Wegovy.
- Obstructive sleep apnea diagnosis? Zepbound has the only FDA OSA label. NovoCare programs do not apply.
- Sleep apnea or cardiovascular history and Medicare? Wait for the July 1, 2026 GLP-1 Bridge Program, which will cover Zepbound KwikPen at roughly $50 a month for eligible beneficiaries.
For a deeper look at the broader options, including telehealth platforms and the now-restricted compounded GLP-1 path, see our guides on tirzepatide compounding pharmacy, cheapest GLP-1 in 2026, and telehealth GLP-1.
Frequently Asked Questions
References
- NovoCare: Wegovy (semaglutide) cost and savings - Novo Nordisk cash-pay program detailing Wegovy pricing for uninsured and underinsured patients.
- NovoCare: Ozempic (semaglutide) cost and savings - Novo Nordisk support program confirming Ozempic has no dedicated weight-loss cash-pay tier.
- Drugs@FDA: Wegovy (semaglutide) approval record, NDA 215256 - FDA approval history for Wegovy.
- Drugs@FDA: Zepbound (tirzepatide) approval record, NDA 217806 - FDA approval history for Zepbound.
- FDA: Medications containing semaglutide for type 2 diabetes or weight loss - FDA guidance on compounded and salt-form (semaglutide sodium/acetate) safety concerns.
- STEP 1 trial: Once-weekly semaglutide in adults with overweight or obesity (NEJM, 2021) - Pivotal data behind semaglutide's ~15% mean weight loss.
- SURMOUNT-1 trial: Tirzepatide once weekly for the treatment of obesity (NEJM, 2022) - Pivotal data behind tirzepatide's ~20% mean weight loss.
- CMS Newsroom - Centers for Medicare & Medicaid Services source for Medicare Part D and GLP-1 coverage policy announcements.